The influence of contralateral occlusion on results of carotid interventions from the Society for Vascular Surgery Vascular Registry  by Ricotta, Joseph J. et al.
From the Society for Vascular SurgeryFrom
V
th
ge
W
th
The
se
Auth
Pres
of
958The inﬂuence of contralateral occlusion on results
of carotid interventions from the Society for
Vascular Surgery Vascular Registry
Joseph J. Ricotta II, MD, MS,a Gilbert R. Upchurch Jr, MD,b Gregg S. Landis, MD,c
Christopher T. Kenwood, MS,d Flora S. Siami, MPH,d Nikolaos Tsilimparis, MD,a John J. Ricotta,e and
Rodney A. White, MD,f Atlanta, Ga; Charlottesville, Va; New York, NY; Watertown, Mass; Washington, D.C.;
and Los Angeles, Calif
Objective: Data on the inﬂuence of contralateral carotid occlusion (CCO) on carotid endarterectomy (CEA) are conﬂicting
and are absent for carotid artery stenting (CAS). This study evaluated the inﬂuence of CCO on CEA and CAS.
Methods:Weevaluatedpatientswith andwithoutCCO in the Society forVascular SurgeryVascularRegistry. Primary outcome
was a composite of periprocedural death, stroke, ormyocardial infarction (MI) (major adverse cardiovascular events [MACE])
and its individual components. Further analysis was done to identify the inﬂuence, if any, of symptom status on outcomes.
Results: There were 1128 CAS and 666 CEA patients with CCO. CAS patients were more often symptomatic with a
greater incidence of coronary artery disease, congestive heart failure, diabetes, chronic obstructive pulmonary disease, and
New York Heart Association class >III. Absolute risk of periprocedural MACE (2.7% for CAS vs 4.2% for CEA), death
(1.1% for CAS vs 0.7% for CEA), stroke (2.1% for CAS vs 3.1% for CEA), and MI (0.3% for CAS vs 0.6% for CEA) was
statistically equivalent for both. This equivalence was maintained when patients with CCO were segregated according to
symptom status and after adjusting for periprocedural risk. There were 16,646 patients without contralateral occlusion
(5698 CAS; 10,948 CEA). Patients without contralateral occlusion with CEA have better outcomes in periprocedural
MACE (1.8% for patients without contralateral occlusion vs 4.2% for patients with CCO), and stroke (1.1% for patients
without contralateral occlusion vs 3.1% for patients with CCO) (P < .0001 for both). In CAS patients, CCO did not
signiﬁcantly affect periprocedural MACE (3.2% for patients without contralateral occlusion vs 2.7% for patients with
CCO), death (0.8% for patients without contralateral occlusion vs 1.0% for patients with CCO), stroke (2.3% for patients
without contralateral occlusion vs 2.1% for patients with CCO), or MI (0.6% for patients without contralateral occlusion
vs 0.3% for patients with CCO). In CEA patients, CCO increased MACE, primarily by increasing stroke rates in
asymptomatic (0.7% vs 2.0%; P [ .0095) and symptomatic (1.7% vs 4.9%; P [ .0012) patients.
Conclusions: Although CEA is preferred in patients without contralateral occlusion, regardless of symptom status, based
on lower rates of periprocedural MACE, death, and stroke, the beneﬁt of CEA is lost in patients with CCO because of
increased stroke rates in CCO patients after CEA but not after CAS regardless of symptom status. The results of CAS and
CEA in patients with CCO are equivalent and within acceptable American Heart Association guidelines. (J Vasc Surg
2014;60:958-65.)Contralateral carotid occlusion (CCO) is encountered
in 2.3% to 25% of patients who undergo carotid revascular-
ization and is widely considered one of the major risk fac-
tors for increased morbidity and stroke for patients who
undergo carotid endarterectomy (CEA).1-6 The North
American Symptomatic Carotid Endarterectomy Trial
(NASCET) identiﬁed an increased risk of perioperative
stroke in patients with CCO of 14% which was more than
twice the risk for patients with a patent contralateral carotid
artery.7 In addition, the Asymptomatic Carotid Artery
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the Society for Vascular Surgery, National Harbor, Md, June 9, 2012.86 surgical) found that these patients did not beneﬁt from
CEA and might have an increased stroke risk.8
With the advent of carotid artery stenting (CAS) as an
alternative treatment modality for carotid stenosis and the
data on CCO from the landmark trials noted previously,
many now advocate for the use of CAS in patients with
CCO, claiming that patients with CCO are at “high risk”
for CEA. The Center for Medicare and Medicaid Services
(CMS) includes CCO among the criteria for patients at
“high risk” for CEA and as an approved indication for
reimbursement for CAS.9Additional material for this article may be found online at www.jvascsurg.org.
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of CEA and CAS remain controversial with a number of
single-center studies claiming no increased risk in patients
with CCO, and a meta-analysis of the literature that suggests
a statistically signiﬁcant but small (2.4%-3.7%) increase in
perioperative stroke rate in the case of a CCO after CEA.10-14
In addition, there is a lack of consensus from the national
professional societies on how best to treat patients with
CCO who are in need of carotid revascularization.15,16
The Society for Vascular Surgery (SVS) Vascular Reg-
istry (VR) on carotid procedures was developed to collect
data on long-term outcomes for patients treated with
CEA and CAS.17,18 In this study, we used the SVS VR
database to determine whether CCO is associated with
an increased risk after CEA and CAS, identify factors asso-
ciated with increased risk, and determine whether CEA or
CAS is better suited for patients with CCO.
METHODS
VR data are reported by participating providers through
Web-based electronic data capture.18 This represents a
group of self-selected individuals and the data are reported
by the site. This database has served as a valuable source of
information on the contemporary practice of CAS and
CEA. The measurement schedule includes baseline (preop-
erative) demographic characteristics, medical history, ca-
rotid symptom status, and preprocedural diagnostic
imaging and laboratory data; procedural (CAS or CEA) in-
formation including clinical utility, and intraoperative and
predischarge complications; and follow-up information
such as postoperative mortality, stroke, myocardial infarc-
tion (MI), and other morbidity. The data from the Vascular
Registry were collected under 45CFR160 through
45CFR164 under administrative data standards and related
requirements under the deﬁnition of Health Care Opera-
tions as a CMS mandate. As such, neither informed consent
nor Institutional Review Board approval was required. All
data entered into the VR are fully compliant with the
Health Insurance Portability and Accountability Act regula-
tions and are auditable. All data reports and analyses per-
formed include only deidentiﬁed and aggregated data.
The New England Research Institutes, Inc (Water-
town, Mass) maintains the online database. Funding for
the administration and database management of the VR
has been provided by the Society for Vascular Surgery.
Outcomes. To provide information required by the
CMS National Coverage Decision, the primary outcome
measure is a composite end point of major adverse cardio-
vascular events (MACE) of death, stroke, and MI. Analysis
of in-hospital and periprocedural outcomes to 30 days after
the procedure was performed for every patient entered in
VR database. Because this is a registry, although deﬁnitions
of stroke and MI are standardized, complications are
identiﬁed and reported from each center and there is no
central adjudication. Stroke is deﬁned as any nonconvulsive,
focal neurological deﬁcit of abrupt onset persisting
>24 hours; speciﬁc brain imaging is not required. The
ischemic event must correspond to a vascular territory. AnMI is classiﬁed as either: (1) Q-wave MI in which one of the
following criteria is required: chest pain or other acute
symptoms consistent with myocardial ischemia and new
pathological Q waves in two or more contiguous electro-
cardiogram leads, or new pathologicQwaves in two ormore
contiguous electrocardiogram leads and an increase in the
level of cardiac enzymes; or (2) non-Q-wave MI, deﬁned as
creatine kinase ratio >2, and creatine kinase-MB >1 in the
absence of new, pathological Q waves.
Procedural success data were also collected. A proce-
dure, either CAS or CEA, is deemed successful when all
of its components are completed without the need of con-
version (CAS to CEA or vice versa) or its abandonment
before completion.
Statistical methods. Tests of statistical signiﬁcance
were conducted with c2 or Fisher exact tests for categorical
variables and analysis of variance for continuous variables.
Descriptive statistics are listed as mean 6 standard devia-
tion for continuous variables and percent (frequency) for
categorical variables. Subset analyses were performed using
the two-tailed t-test for continuous variables and the c2 or
Fisher exact, as necessary, for discrete/categorical data. Un-
adjusted and adjusted odds ratios (ORs) were used to
compare the primary outcomes across treatment groups. ORs
were adjusted for CCO and any signiﬁcant baseline factors
that were kept after using backward elimination methods.
Differences were considered signiﬁcant if P < .05. All statis-
tical analyses were performed by New England Research
Institutes, Inc, using SAS Statistical Software (Cary, NC).
RESULTS
Between July 2005 andDecember 2011, 18,440 carotid
interventions were registered in the SVSVR. These included
11,614 CEA and 6826 CAS procedures. CCO was present
in 1794 patients (9.8%) and speciﬁcally in 6% of CEA pa-
tients and in 16% of CAS patients. In the group of patients
with CCO, there were no procedural failures or conversions.
The demographic characteristics of the groups are
shown in detail in Table I (detailed demographic character-
istics and medical history is shown in Supplementary
Table I, online only). Patients with CCO were symptom-
atic on the ipsilateral side in 48.7% of the cases (n ¼ 873).
A shunt during CEA was used in 63.5% of patients with
CCO and in 55.7% of patients without CCO.
In bivariate analysis, patients with CCO had a signiﬁ-
cantly greater risk of MACE, death, or stroke compared
with patients without CCO (Table II). Patients who un-
derwent CEA were more likely to suffer a stroke or
MACE if they had a CCO, and patients who underwent
CAS did not have a greater frequency of adverse events if
a CCO was present (Table III).
However, in the regression analysis, CCO was not an
independent risk factor for the combined end point
(MACE) in the entire cohort (P¼ .13) or in the subgroups
of symptomatic (P ¼ .62) and asymptomatic patients
(P ¼ .076) (Table IV). In addition, CCO did not signiﬁ-
cantly affect the incidence of stroke in the entire cohort
(P ¼ .057) or in the subgroup of asymptomatic patients
Table I. Demographic characteristics of patients with and without contralateral carotid occlusion (CCO) who underwent
carotid endarterectomy (CEA) or carotid artery stenting (CAS)
CCO Non-CCO
CAS (n ¼ 1128) CEA (n ¼ 666) Pa CAS (n ¼ 5698) CEA (n ¼ 10,948) Pa
Mean age (range), years 69.8 (28-99) 70.2 (23-96) .4310 71.0 (24-98) 70.6 (18-96) .0105
Male sex 64.0 (722) 62.8 (418) .6118 60.4 (3441) 59.0 (6457/10,948) .0807
Etiology
Atherosclerosis 84.6 (954) 97.6 (650) <.0001 68.0 (3875) 98.3 (10,759/10,948) <.0001
Radiation 3.1 (35) 0.2 (1) 5.1 (292) 0.2 (18/10,948)
Restenosis 11.5 (130) 1.8 (12) 24.0 (1368) 1.1 (123/10,948)
Symptomatic 53.8 (607) 39.9 (266) <.0001 45.5 (2594) 38.1 (4170/10,947) <.0001
CAD 59.0 (666) 52.7 (351) .0090 59.8 (3406) 48.1 (5267/10,948) <.0001
MI 21.0 (237) 18.8 (125) .2732 21.6 (1232) 16.3 (1785/10,948) <.0001
CHF 14.2 (160) 8.4 (56) .0002 14.3 (816) 7.4 (808/10,948) <.0001
Hypertension 84.8 (957) 87.2 (581) .1632 82.7 (4710) 83.5 (9147/10,948) .1489
Diabetes 35.7 (403) 31.1 (207) .0499 34.7 (1979) 31.7 (3467/10,948) <.0001
TIA 22.6 (255) 21.0 (140) .4439 21.9 (1250) 17.8 (1954/10,948) <.0001
Stroke 31.2 (352) 28.2 (188) .2011 24.2 (1379) 19.3 (2112/10,948) <.0001
COPD 22.6 (255) 18.3 (122) .0357 20.7 (1181) 17.9 (1965/10,948) <.0001
Cancer 15.1 (170) 11.7 (78) .0476 19.3 (1100) 12.7 (1393/10,948) <.0001
NYHA class
#2 87.8 (990) 91.6 (610) .0118 88.1 (5018) 95.6 (10,471/10,948) <.0001
>2 12.2 (138) 8.4 (56) 11.9 (680) 4.4 (477/10,948)
Aspirin or clopidogrel 94.3 (1064) 80.6 (537) <.0001 94.6 (5389) 84.1 (9206/10,948) <.0001
Age $80 years 19.1 (215) 15.8 (105) .0848 20.0 (1140) 20.1 (2196/10,948) .9512
CAD, Coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; NYHA, New York
Heart Association; TIA, transient ischemic attack.
Data are presented as percentage (No.) except where otherwise stated.
aP value for age was determined using a t-test. All others were determined using Fisher exact test.
Table II. Adverse events at 30 days or at hospital
discharge according to contralateral carotid status
(contralateral carotid occlusion [CCO] vs non-CCO) for
all patients
In-hospital
adverse event
CCO (n ¼ 1794),
% (No.)
Non-CCO
(n ¼ 16,646),
% (No.) Pa
Death, stroke, or MI 3.3 (59) 2.2 (373) .0083
Mortality 0.9 (17) 0.5 (83) .0255
Stroke 2.5 (45) 1.5 (247) .0019
MI 0.4 (8) 0.6 (103) .5184
MI, Myocardial infarction.
Events are deﬁned as any intraoperative or predischarge event recorded on
Procedure forms. The event rates are per patient.
aP values were determined using Fisher exact test.
Table III. Adverse events at 30 days or at hospital
discharge according to procedure and treatment arm
In-hospital adverse event Procedure
PaCAS patients
CCO (n ¼ 1128),
% (No.)
Non-CCO
(n ¼ 5698,
% (No.)
Death, stroke, or MI 2.7 (31) 3.2 (180) .5107
Mortality 1.1 (12) 0.8 (45) .3692
Stroke 2.1 (24) 2.3 (131) .8268
MI 0.3 (4) 0.6 (33) .5042
CEA patients
CCO (n ¼ 666),
% (No.)
Non-CCO
(n ¼ 10,948),
% (No.) Pa
Death, stroke, or MI 4.2 (28) 1.8 (193) <.0001
Mortality 0.7 (5) 0.3 (38) .0979
Stroke 3.1 (21) 1.1 (116) <.0001
MI 0.6 (4) 0.6 (70) >.9999
CAS, Carotid artery stenting; CCO, contralateral carotid occlusion; CEA,
carotid endarterectomy; MI, myocardial infarction.
Events are any intraoperative or predischarge event recorded on Procedure
forms. The event rates are per patient.
aP values were based on Fisher exact test.
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CCO was associated with a 1.49 times greater risk of stroke
(P ¼ .049).
In the entire cohort, CAS was associated with greater
risk of MACE, mortality, and stroke in multivariable anal-
ysis (Table IV). In the adjusted regression analysis used to
investigate MACE in the subgroup of CCO patients, the
type of procedure (CEA vs CAS) was not statistically signif-
icant (OR, 1.69; 95% conﬁdence interval [CI], 1-2.87;
P > .05) even before any correction for multiple analyses
that would require lowering the threshold for statistical sig-
niﬁcance to <.05. The same applied when investigatingstroke alone as an end point in the subgroup of patients
with CCO in a regression model adjusting for symptomatic
disease (CEA vs CAS: OR, 1.73; 95% CI, 0.95-3.15; P ¼
.075). All available preoperative parameters were explored,
Table IV. Multivariable logistic models for in-hospital death/stroke/myocardial infarction (MI) and stroke alone
In-hospital death/stroke/MI In-hospital stroke
OR CI P OR CI P
Entire cohort
CAS vs CEA 1.39 1.14-1.70 .0013 1.74 1.37-2.21 <.0001
CCO 1.25 0.94-1.66 .1311 1.38 0.99-1.91 .0572
Symptomatic 1.79 1.48-2.18 <.0001 2.12 1.67-2.69 <.0001
White race 0.49 0.37-0.63 <.0001 0.51 0.37-0.70 <.0001
CAD 1.24 1.01-1.52 .0434 e e e
CHF 1.29 0.98-1.70 .0743 e e e
Diabetes 1.40 1.14-1.70 .0011 1.44 1.13-1.82 .0027
NYHA >2 vs #2 1.49 1.11-2.01 .0083 e e e
Age $80 years 1.47 1.18-1.84 .0006 1.51 1.16-1.97 .0023
Symptomatic patients
CAS vs CEA 1.52 1.17-1.98 .0017 1.56 1.15-2.11 .0042
CCO 1.10 0.75-1.61 .6181 1.49 1.00-2.22 .0494
White race 0.51 0.36-0.72 .0001 0.57 0.37-0.85 .0066
CHF 1.53 1.08-2.18 .0174 e e e
Age $80 years 1.35 1.00-1.81 .0489 e e e
Asymptomatic patients
CAS vs CEA 1.32 0.97-1.78 .0759 1.99 1.36-2.92 .0004
CCO 1.50 0.97-2.32 .0703 1.14 0.63-2.07 .6551
White race 0.44 0.29-0.66 <.0001 0.43 0.26-0.72 .0014
CAD 1.35 0.98-1.87 .0627 e e e
VHD 1.48 0.94-2.33 .0891 e e e
Diabetes 1.89 1.40-2.54 <.0001 2.26 1.54-3.30 <.0001
NYHA class >2 vs #2 2.04 1.35-3.10 .0008 1.74 1.00-3.00 .0490
Age $80 years 1.64 1.17-2.28 .0036 1.92 1.27-2.91 .0019
CCO patients
CEA vs CAS 1.69 1.00-2.87 .0502 1.73 0.95-3.15 .0748
Symptomatic 1.55 0.91-2.64 .1040 2.87 1.49-5.54 .0017
Diabetes 1.59 0.94-2.69 .0841 e e e
Symptomatic CCO patients
CEA vs CAS 1.58 0.79-3.19 .1993 1.55 0.75-3.19 .2341
Arrhythmia 2.02 0.89-4.59 .0928 1.83 0.77-4.33 .1722
Asymptomatic CCO patients
CEA vs CAS 1.76 0.79-3.94 .1684 2.35 0.75-7.31 .1418
Diabetes 3.18 1.41-7.17 .0054 3.10 0.99-9.69 .0516
NYHA class >2 e e e 2.55 0.67-9.72 .1690
CAD, Coronary artery disease; CAS, carotid artery stenting; CCO, contralateral carotid occlusion; CEA, carotid endarterectomy; CHF, congestive heart
failure; CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; NYHA, New York Heart Association; OR, odds ratio; VHD, valvular heart
disease.
Variable list: procedure type, CCO, symptomatic, race (white), VHD, CAD, CHF, diabetes, NYHA, age $80 years, arrhythmia, atherosclerosis, COPD, and
cancer.
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diabetes (Table IV). Symptomatic disease was an indepen-
dent risk factor for stroke in patients with CCO, with an
OR of 2.87 (95% CI, 1.49-5.54; P ¼ .0017).
The effect of CCO as opposed to a contralateral carotid
artery with >70% stenosis was also investigated by running
the regression model with the contralateral side as a
categorical variable with variable options: (1) contralateral
carotid stenosis <70%, (2) contralateral carotid stenosis
$70%, or (3) CCO. Contralateral carotid stenosis <70%
was present in 77.3% of the cases, stenosis >70% in
12.9%, and CCO in 9.8% of the cases (Table V).
The OR for MACE was 1.3 in patients with contralat-
eral stenosis>70% and in those with CCO. Therefore, these
patients appeared to have equivalent risk compared with pa-
tients with contralateral stenosis <70%. The OR for stroke
was 1.3 in patients with stenosis >70% compared with thereference group with contralateral stenosis <70%, and the
OR was slightly greater at 1.44 in patients with CCO.
Among CEA patients, a shunt was used in 63.5% of pa-
tients with CCO vs 57.2% of patients with >70% stenosis
and 55.3% of patients without or <70% contralateral steno-
sis. Shunts were signiﬁcantly more frequently used for
CEA patients with CCO compared with CEA patients
with >70% or <70% contralateral carotid stenosis (P <
.0001). The outcomes with and without the use of a shunt
were investigated by comparing MACE and the individual
end points (mortality, stroke, MI) in bivariate analysis in
the entire CEA cohort and in the subgroups of symptomatic
and asymptomatic patients with CCO (Supplementary
Table II, online only). MACE were not statistically different
in patients with CCOwhen stratiﬁed according to shunt use
(5% with shunt vs 2.9% without shunt; P > .1). The analysis
yielded no difference in outcome between use and no use of
Table V. Multivariable logistic models for in-hospital death/stroke/myocardial infarction (MI) and stroke alone with
contralateral lesion as a three-category value
Death/stroke/MI Stroke
OR CI P OR CI P
Entire cohort
CAS vs CEA 1.38 1.13-1.69 .0016 1.72 1.35-2.18 <.0001
Stenosis <70% Ref Ref Ref Ref Ref
Stenosis $70% vs <70% 1.31 1.00-1.72 .0502 1.31 0.94-1.83 .0452
CCO vs stenosis <70% 1.30 0.98-1.74 1.44 1.03-2.02
Symptomatic 1.80 1.48-2.19 <.0001 2.15 1.69-2.74 <.0001
White race 0.48 0.37-0.62 <.0001 0.50 0.36-0.69 <.0001
CAD 1.23 1.00-1.51 .0480 e e e
CHF 1.27 0.96-1.68 .0990 e e e
Diabetes 1.40 1.15-1.71 .0010 1.43 1.13-1.82 .0030
NYHA >2 vs #2 1.50 1.12-2.02 .0073 e e e
Age $80 years 1.49 1.19-1.86 .0004 1.53 1.17-1.99 .0019
Symptomatic patients
CAS vs CEA 1.54 1.18-2.00 .0013 1.56 1.15-2.12 .0041
Stenosis <70% Ref Ref Ref Ref Ref Ref
Stenosis $70% vs <70% 1.20 0.83-1.75 .5629 1.16 0.74-1.82 .1254
CCO vs stenosis <70% 1.13 0.77-1.65 1.52 1.01-2.27
White race 0.50 0.35-0.71 <.0001 0.56 0.37-0.85 .0061
CHF 1.53 1.08-2.18 .0176 e e e
Age $80 years 1.35 1.00-1.82 .0467 e e e
Asymptomatic patients
CAS vs CEA 1.27 0.94-1.73 .1245 1.90 1.29-2.80 .0011
Stenosis <70% Ref Ref Ref Ref Ref Ref
Stenosis $70% vs <70% 1.47 0.99-2.19 .0311 1.51 0.92-2.48 .2447
CCO vs stenosis <70% 1.62 1.04-2.52 1.25 0.69-2.29
White race 0.43 0.28-0.64 <.0001 0.42 0.25-0.70 .0010
CAD 1.36 0.99-1.88 .0589 e e e
VHD 1.48 0.94-2.32 .0920 e e e
Diabetes 1.89 1.40-2.54 <.0001 2.26 1.54-3.31 <.0001
NYHA >2 vs #2 2.05 1.35-3.12 .0008 1.76 1.01-3.05 .0446
Age $80 years 1.67 1.19-2.33 .0027 1.98 1.31-2.99 .0013
CAD, Coronary artery disease; CAS, carotid artery stenting; CCO, contralateral carotid occlusion; CEA, carotid endarterectomy; CHF, congestive heart
failure; CI, conﬁdence interval; NYHA, New York Heart Association; OR, odds ratio; Ref, reference; VHD, valvular heart disease.
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tients were symptomatic or not (P > .1). Although no in-
formation is available in the SVS VR regarding selective or
routine use of a shunt, patients with the use of a shunt
had outcomes similar to those without the use of a shunt,
suggesting either that that the use of a shunt sufﬁciently
compensated for the CCO or that the shunt does not pro-
vide an obvious beneﬁt. This cannot be clariﬁed from the
data presently available in our database.
DISCUSSION
Prospective randomized trials have shown superiority of
CEA over CAS in reduction of stroke, but not MACE, in
symptomatic and asymptomatic indviduals.4,15,19,20 How-
ever, these trials did not speciﬁcally address the issue of ca-
rotid intervention in the face of CCO. Data from the
NASCET suggest that patients with CCO are at increased
risk of stroke after CEA and these data were initially used
to support CCO as a “high risk” anatomic condition that
was an indication for CAS.7 Several other large single-
center studies have reported excellent results after CEA in
patients with CCO.10-13 In a meta-analysis review of CEAseries that compared patients with and without CCO, Kretz
et al identiﬁed only one study that reported a difference in
outcome between patients with and without CCO.21 In
contrast, Halm et al demonstrated that a contralateral ste-
nosis >50% was an independent risk factor for MACE
and especially for stroke22; and Maatz et al reported in a
meta-analysis of 13,438 CEA procedures a signiﬁcantly
greater perioperative stroke rate after CEA of 3.7%
compared with 2.4% (P ¼ .002) in the presence of a
CCO.14 This question is of particular importance because
CCO is one of the factors that CMS uses to identify patients
at high risk for CEA and qualify them for reimbursement of
CAS. There are a paucity of data published on outcomes of
CAS in patients with CCO.14,21-28
There might be many potential reasons that CCO
would be associated with greater risk of postoperative com-
plications. Patients who undergo carotid intervention in
the face of CCO have bilateral carotid disease by deﬁnition
and might therefore have an increased overall burden of
cardiovascular risk and, in particular, intracranial and/or
extracranial disease. The presence of CCO could inﬂuence
intracranial collateral pathways and intraoperative or
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are more likely to have reduced hemispheric blood ﬂow
during carotid cross-clamping. Kretz et al identiﬁed occlu-
sion of the contralateral carotid artery as the sole predictor
of intolerance to clamping in bivariate and multivariate an-
alyses.21 It is certainly possible that a patient who suffered a
postoperative carotid thrombosis would be more likely to
remain asymptomatic in the face of CCO. One can specu-
late that these factors might have inﬂuenced the results in
the NASCET, a study undertaken when the use of intrao-
perative shunting and patch closure were less well standard-
ized. In the SVS VR, shunt use was more common in the
patients with CCO. However, as with many previous
studies, we could not prove or disprove the beneﬁt of selec-
tive shunt use in reducing perioperative events. Finally, one
can speculate that symptomatic patients with CCO might
well have reduced baseline cerebral reserve and be at risk
for reperfusion injury after successful revascularization.
Our data do not support a speciﬁc increased risk associated
with CCO but do support the concept of CCO as a marker
for increased cardiovascular risk burden. Although analysis
of overall risk of stroke and MACE shows an increased risk
of postoperative events when CCO was considered as the
only variable, this was not borne out in multivariate analysis
(Table IV). Data presented in Table I indicate that the de-
mographic characteristics and risk proﬁle of patients with
and without CCO are not different. However, the concept
of “increased burden of disease” is supported by the anal-
ysis done in Table V that shows no difference in risk of
stroke or MACE between patients with CCO and those
with contralateral stenosis >70%.4,6,12,13
To out knowledge, this study comprises one of the
largest series of patients with CCO for CEA and CAS
ever reported. In this study we have used data from the
SVS VR to evaluate the effect of CCO on patients under-
going either CAS or CEA. We demonstrate that patients
with CCO are equally likely to suffer a MACE or stroke
regardless of type of intervention (CEA or CAS). In these
patients, the results after CEA are not different than after
CAS. Furthermore, we demonstrated that the effect of
CCO in the investigated cohort was also similar to the ef-
fect of contralateral carotid stenosis >70%.
Our data show equivalent outcomes between CEA and
CAS in patients with CCO. This is primarily the result of
increased MACE and strokes in CEA patients with CCO
compared with those who undergo CEA in the absence
of CCO.
Several limitations of this study warrant further discus-
sion. The main limitation in this study is that data from reg-
istries such as the SVS VR are not designed to mimic
clinical trials. As such, not all clinical factors that result in
treatment bias can be readily identiﬁed. Anatomic informa-
tion (such as plaque characteristic, degree of vessel tortuos-
ity, calciﬁcation) and other important factors (such as
operator experience) were not available, and any confound-
ing effects these factors might have had on the study out-
comes cannot be adequately analyzed. There are also
limitations speciﬁc to secondary data analyses of a databasesuch as the SVS VR. It must be noted that data were re-
ported by treating physicians/institutions. The potential ef-
fect of reporting bias within the registry has previously been
investigated and discussed.18 Finally, as with all studies us-
ing registry data, all collected information is retrospective in
nature. However, in the absence of randomized evidence,
data from independent and veriﬁable registries can provide
valuable information about clinical outcomes.
CONCLUSIONS
In this very large analysis of “real-world” results, CCO
is associated with increased risk of MACE and stroke after
CEA and CAS. However, it appears that CCO itself is not a
risk factor, but rather a marker of increased perioperative
risk. CEA is preferred over CAS in patients without CCO
regardless of symptom status, based on less periprocedural
MACE, death, and stroke. However, the beneﬁt of CEA is
lost in patients with CCO because of increased stroke rates
in CCO patients after CEA, but not CAS regardless of
symptom status. The results of CAS and CEA in patients
with CCO are equivalent and within acceptable American
Heart Association guidelines. Based on the results of our
study, the argument that CAS should be preferred over
CEA for patients with CCO is not valid. Our data suggest
that CAS and CEA are equivalent intervention strategies in
patients with CCO and that the choice between the two
should be made on the basis of operator expertise. The in-
ﬂuence of CCO on outcomes after carotid intervention
should be re-evaluated and further investigated in future
prospective randomized studies that speciﬁcally stratify pa-
tients according to patency of contralateral carotid artery.
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at www.jvascsurg.org.DISCUSSIONDr R. Clement Darling (Albany, NY ). The ﬁrst question I
would have for you, Joe, is do you have any information on those
patients with high-grade stenosis contralateral carotid stenosis as
opposed to just occlusion? Is there any differentiation between a
<50 and a >90?
Dr Joseph J. Ricotta. We are currently investigating that but
do not have the answer for presentation today. We will include it in
the manuscript.
DrHani Slim (London, United Kingdom). I’m sorry, I missed
the information, did you look at the state of the vertebral arteries?
Dr Ricotta. This is a registry database. We have information
on carotid imaging, for exampleultrasound, computed tomography,and magnetic resonance in terms of whether they are patent or
occluded and how stenosed they are, but we do not have any data
on the vertebral arteries.
Dr Christos Liapis (Athens, Greece). Can you please give us
an indication whether the contralateral occluded side was symp-
tomatic or asymptomatic and if this had any inﬂuence in the
outcome of the procedures.
Dr Ricotta. A few of the slides I showed were of the contra-
lateral patients according to their symptom status, and there was
no difference for patients without symptoms or with symptoms if
you compare carotid artery stenting (CAS) and carotid endarterec-
tomy (CEA). But if you take the CEA cohort, the symptomatic
JOURNAL OF VASCULAR SURGERY
Volume 60, Number 4 Ricotta et al 965patients did worse. For CEA, the risk of stroke increased from 2%
to 4.9% for symptomatic patients with contralateral carotid occlu-
sion compared with asymptomatic patients with contralateral oc-
clusion. And for CAS, if you are asymptomatic, you had a 1%
stroke risk versus a 3% stroke risk if you were symptomatic in the
contralateral occlusion group. But if you compare CAS with
CEA in the setting of contralateral occlusion, there was no differ-
ence regardless of symptoms.
Dr Liapis. Maybe I was not clear. I was referring to symptom-
atology from the occluded side, previous symptomatology, whether
the totally occluded side had produced any symptoms or not.
Dr Ricotta. Preprocedural symptoms.
Dr Liapis. That is correct, in the occluded side, in the totally
occluded side. If it was an asymptomatic total occlusion or a symp-
tomatic total occlusion.
Dr Ricotta. We have data to show whether patients were
symptomatic preprocedurally and whether they presented with
transient ischemic attack or stroke. I showed this in the ﬁrst table;
the CAS patients were more symptomatic preprocedure, but it was
not known whether it was from the ipsilateral or the contralateral
carotid artery.
Dr Donald Jacobs (St. Louis, Mo). Good presentation, and I
think we all believe that this was probably the softest indication for
carotid stenting as a high-risk criteria. But I have an issue with one
of your conclusions that shunting did not matter with CEA. And
the problem with that is that you do not know why they were
shunted. So not knowing the indications or the thought process
behind that, I think it is too big a step to say that shunting with
contralateral occlusion did not have an effect. If I can get your
comment on that.
Dr Ricotta. I think that is a good point. And I think that
based on the data, shunting did not matter.
We looked into the database and you cannot identify the
reason for people’s shunting. So did they shunt because they had
symptoms or did they shunt because they routinely shunt every
time they perform surgery?
All we know is that the patients that were shunted did not do
better statistically than the patients that were not shunted in the
asymptomatic and the symptomatic groups. It is impossible to
know from the database why that is. I would venture to guess
that, perhaps, similar to the study that was published last year by
the New England Study Group that showed that patients who
get shunted by people who do not routinely shunt do worse.
Routine shunters will probably get better results than those whoselectively shunt and then have to do so rather quickly after the ca-
rotid artery is cross-clamped and there are electrocardiographic
(EEG) changes, for example.
Dr Jacobs. Well, again, I think the problem with that is that if
you selectively shunt, those are the patients that are more likely to
have trouble because they have shown you some sign of having
ischemia.
Dr Marat Goldenberg (Chester, Pa). My question is a
follow-up to the previous question. Was there any information
available as to the people that did not shunt? Did they do the sur-
gery awake or did they use EEG monitoring? And if they used
EEG monitoring, what were the ﬁndings during the procedures.
Were any changes associated with periprocedural or postproce-
dural strokes?
Dr Ricotta. In the registry, approximately 5% to 7% of the pa-
tients received the procedure awake; in the rest of them the proce-
dure was performed using general anesthesia. I don’t have the
breakdown in terms of the patients that were shunteddhow
many were done awake and how many were not. For the overall
CEA groupd11,000-plus patientsd90% or more were performed
using general anesthesia.
Dr Walter Dorigo (Florence, Italy). Did you investigate in
your analysis only ipsilateral strokes or also contralateral strokes?
And if yes, did you ﬁnd a difference between occluded or nonoc-
cluded contralateral carotid artery?
Dr Ricotta. Again, there is no way to tell from the database
the territory of stroke. We just know that the patients either had
a stroke or did not have a stroke.
Dr Sateesh Babu (Hawthorne, NY). One of the clinical syn-
dromes in this particular group of patientsdthe high-grade steno-
sis ipsilateral and contralateral occlusiondis the hyperperfusion
syndrome that we are all concerned about. That is one of the rea-
sons why we would like to keep the hemodynamics as near normal
as possible and one of the reasons to shunt in my opinion. So did
you get any idea from this database whether the hyperfusion syn-
drome was seen in any one of these, because it is such a large
groupdand I hope that they did not mistake this for stroke.
Dr Ricotta. Again, these are patient records that are entered
into a database, and stroke was deﬁned as a neurologic insult >24
hours. You cannot tell from the database if the stroke was embolic,
ischemic, or from hyperperfusion, but as I am sure you are aware,
most strokes after CEA are embolic in nature. This is a limitation
of a database study. The power of the study is in the large number
of patients.
Supplementary Table I (online only). Demographic characteristics of patients with and without contralateral carotid
occlusion (CCO) who underwent carotid endarterectomy (CEA) or carotid artery stenting (CAS)
Characteristic
CCO Non-CCO
CAS (n ¼ 1128) CEA (n ¼ 666) Pa CAS (n ¼ 5698) CEA (n ¼ 10,948) Pa
Mean age (range), years 69.8 (28-99) 70.2 (23-96) .4310 71.0 (24-98) 70.6 (18-96) .0105
Gender, male 64.0 (722) 62.8 (418) .6118 60.4 (3441) 59.0 (6457/10,948) .0807
Race, white/Caucasian 92.6 (1045) 88.4 (589) .0034 91.9 (5238) 91.7 (10043/10,948) .6769
Ethnicity, Hispanic 4.4 (50) 4.2 (28) .9048 4.4 (250) 3.8 (420/10,948) .0885
Etiology
Atherosclerosis 84.6 (954) 97.6 (650) <.0001 68.0 (3875) 98.3 (10759/10,948) <.0001
Dissection 0.2 (2) 0.2 (1) 1.0 (57) 0.1 (10/10,948)
Fibromuscular dysplasia 0.2 (2) 0.0 (0) 0.1 (8) 0.0 (5/10,948)
Radiation 3.1 (35) 0.2 (1) 5.1 (292) 0.2 (18/10,948)
Trauma 0.1 (1) 0.0 (0) 0.3 (19) 0.0 (2/10,948)
Restenosis 11.5 (130) 1.8 (12) 24.0 (1368) 1.1 (123/10,948)
Other 0.4 (4) 0.3 (2) 1.4 (79) 0.3 (31/10,948)
Symptomatic 53.8 (607) 39.9 (266) <.0001 45.5 (2594) 38.1 (4170/10,947) <.0001
CAD 59.0 (666) 52.7 (351) .0090 59.8 (3406) 48.1 (5267/10,948) <.0001
MI 21.0 (237) 18.8 (125) .2732 21.6 (1232) 16.3 (1785/10,948) <.0001
VHD 4.7 (53) 8.1 (54) .0038 6.9 (394) 7.4 (806/10,948) .2974
Arrhythmia 12.2 (138) 15.9 (106) .0323 15.0 (852) 12.4 (1362/10,948) <.0001
CHF 14.2 (160) 8.4 (56) .0002 14.3 (816) 7.4 (808/10,948) <.0001
Hypertension 84.8 (957) 87.2 (581) .1632 82.7 (4710) 83.5 (9147/10,948) .1489
Diabetes 35.7 (403) 31.1 (207) .0499 34.7 (1979) 31.7 (3467/10,948) <.0001
TIA 22.6 (255) 21.0 (140) .4439 21.9 (1250) 17.8 (1954/10,948) <.0001
Stroke 31.2 (352) 28.2 (188) .2011 24.2 (1379) 19.3 (2112/10,948) <.0001
COPD 22.6 (255) 18.3 (122) .0357 20.7 (1181) 17.9 (1965/10,948) <.0001
CRF 3.5 (40) 2.0 (13) .0605 3.7 (209) 3.2 (349/10,948) .1026
TMB 7.1 (80) 7.8 (52) .5756 6.5 (369) 5.6 (617/10,948) .0319
PVD 43.1 (486) 41.1 (274) .4292 37.2 (2120) 38.7 (4237/10,948) .0597
GI ulcer/bleeding 2.6 (29) 2.9 (19) .7627 3.9 (223) 2.8 (308/10,948) .0002
Current or past smoker 64.9 (732) 68.2 (454) .1636 58.9 (3354) 57.8 (6333/10,948) .2083
Cancer 15.1 (170) 11.7 (78) .0476 19.3 (1100) 12.7 (1393/10,948) <.0001
Coagulopathy 1.0 (11) 1.8 (12) .1909 1.0 (57) 1.3 (139/10,948) .1305
ASA grade
#3 83.9 (946) 83.9 (559) >.9999 87.7 (4997) 88.4 (9683/10,948) .1565
>3 16.1 (182) 16.1 (107) 12.3 (701) 11.6 (1265/10,948)
NYHA score
#2 87.8 (990) 91.6 (610) .0118 88.1 (5018) 95.6 (10471/10,948) <.0001
>2 12.2 (138) 8.4 (56) 11.9 (680) 4.4 (477/10,948)
Aspirin 85.3 (962) 74.8 (498) <.0001 84.6 (4823) 78.2 (8561/10,948) <.0001
Clopidogrel 75.5 (852) 28.4 (189) <.0001 76.6 (4362) 24.5 (2681/10,948) <.0001
Aspirin or clopidogrel 94.3 (1064) 80.6 (537) <.0001 94.6 (5389) 84.1 (9206/10,948) <.0001
Age $80 years 19.1 (215) 15.8 (105) .0848 20.0 (1140) 20.1 (2196/10948) .9512
Locoregional anesthesia e 17.4 (116) e e 23.5 (2577/10,947) e
Use of shunt e 63.5 (423)b e e 55.7 (6096/10,945)b e
ASA, American Society of Anesthesiologists; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease;
CRF, chronic renal failure; GI, gastrointestinal; MI, myocardial infarction; NYHA, New York Heart Association; PVD, peripheral vascular disease; TIA,
transient ischemic attack; TMB, transient monocular blindness; VHD, valvular heart disease.
Data are presented as percentage (No.) except where otherwise stated.
aP value for age was determined using a t-test. All others were determined using Fisher exact test.
bP value for use of shunt <.0001.
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Supplementary Table II (online only). Inﬂuence of shunt on major adverse cardiovascular event (MACE) in all patients
with contralateral carotid occlusion (CCO) and according to symptomatic status
CCO in-hospital adverse event
CEA contralateral patients
Shunt used (n ¼ 423), % (No.) No shunt used (n ¼ 243), % (No.) Pa
All CEA contralateral patients
Death, stroke, or MI 5.0% (21/423) 2.9% (7/243) .2325
Mortality 0.7% (3/423) 0.8% (2/243) >.9999
Stroke 3.8% (16/423) 2.1% (5/243) .2569
MI 0.7% (3/423) 0.4% (1/243) >.9999
Symptomatic patients
Death, stroke, or MI 6.0% (11/184) 3.7% (3/82) .5603
Mortality 0.5% (1/184) 1.2% (1/82) .5223
Stroke 5.4% (10/184) 3.7% (3/82) .7599
MI 0.0% (0/184) 0.0% (0/82) N/A
Asymptomatic patients
Death, stroke, or MI 4.2% (10/239) 2.5% (4/161) .4194
Mortality 0.8% (2/239) 0.6% (1/161) >.9999
Stroke 2.5% (6/239) 1.2% (2/161) .4833
MI 1.3% (3/239) 0.6% (1/161) .6514
CEA, Carotid endarterectomy; MI, myocardial infarction.
Events are any recorded on Procedure forms either intraoperatively or before discharge. Event rates are per patient.
aP values were determined using Fisher exact test.
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